 Julie Fitzgerald
Concepts (432)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sepsis | 40 | 2022 | 305 | 7.650 |
Why?
| | Shock, Septic | 26 | 2022 | 100 | 5.090 |
Why?
| | Acute Kidney Injury | 17 | 2021 | 275 | 3.850 |
Why?
| | Intensive Care Units, Pediatric | 29 | 2021 | 98 | 3.020 |
Why?
| | Child | 98 | 2022 | 6928 | 2.840 |
Why?
| | Systemic Inflammatory Response Syndrome | 12 | 2022 | 45 | 2.490 |
Why?
| | Child, Preschool | 61 | 2022 | 3811 | 2.170 |
Why?
| | Multiple Organ Failure | 9 | 2022 | 45 | 2.000 |
Why?
| | Infant | 49 | 2022 | 3157 | 1.860 |
Why?
| | Hospital Mortality | 15 | 2020 | 336 | 1.590 |
Why?
| | Hypotension | 2 | 2020 | 75 | 1.500 |
Why?
| | Critical Care | 13 | 2022 | 371 | 1.460 |
Why?
| | Adolescent | 54 | 2022 | 9293 | 1.310 |
Why?
| | Hematopoietic Stem Cell Transplantation | 11 | 2022 | 831 | 1.220 |
Why?
| | Vancomycin | 4 | 2022 | 94 | 1.160 |
Why?
| | Anti-Bacterial Agents | 10 | 2022 | 829 | 1.110 |
Why?
| | Retrospective Studies | 40 | 2022 | 7883 | 1.080 |
Why?
| | Respiratory Insufficiency | 7 | 2022 | 157 | 1.050 |
Why?
| | Cytokines | 6 | 2022 | 780 | 1.020 |
Why?
| | Heart Arrest | 4 | 2019 | 269 | 0.990 |
Why?
| | Kidney Diseases | 3 | 2022 | 425 | 0.980 |
Why?
| | Bacterial Infections | 3 | 2020 | 228 | 0.930 |
Why?
| | Humans | 109 | 2022 | 84808 | 0.930 |
Why?
| | Severity of Illness Index | 19 | 2021 | 1793 | 0.920 |
Why?
| | Critical Illness | 12 | 2022 | 286 | 0.920 |
Why?
| | Hospitals, Pediatric | 11 | 2022 | 97 | 0.910 |
Why?
| | Shock | 3 | 2021 | 51 | 0.890 |
Why?
| | Intensive Care Units | 6 | 2022 | 379 | 0.840 |
Why?
| | Male | 69 | 2022 | 42330 | 0.810 |
Why?
| | Immunocompromised Host | 1 | 2020 | 145 | 0.770 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2019 | 324 | 0.770 |
Why?
| | Prospective Studies | 24 | 2022 | 4139 | 0.750 |
Why?
| | Databases as Topic | 1 | 2019 | 94 | 0.740 |
Why?
| | Female | 66 | 2022 | 45277 | 0.740 |
Why?
| | Intubation, Intratracheal | 5 | 2022 | 147 | 0.720 |
Why?
| | Vaccination | 1 | 2020 | 253 | 0.710 |
Why?
| | Adaptation, Psychological | 1 | 2018 | 158 | 0.670 |
Why?
| | Infant, Newborn | 16 | 2022 | 2472 | 0.650 |
Why?
| | Heart Diseases | 1 | 2019 | 315 | 0.620 |
Why?
| | Leukemia | 1 | 2018 | 307 | 0.620 |
Why?
| | Risk Factors | 16 | 2022 | 5482 | 0.610 |
Why?
| | High-Frequency Ventilation | 2 | 2013 | 9 | 0.600 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 234 | 0.580 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2017 | 130 | 0.580 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2017 | 402 | 0.580 |
Why?
| | Cross-Sectional Studies | 8 | 2019 | 1468 | 0.480 |
Why?
| | Immunotherapy | 4 | 2021 | 593 | 0.470 |
Why?
| | Prognosis | 14 | 2022 | 3735 | 0.450 |
Why?
| | Respiration, Artificial | 7 | 2020 | 334 | 0.450 |
Why?
| | Quality of Life | 2 | 2020 | 1394 | 0.450 |
Why?
| | Emergencies | 1 | 2011 | 113 | 0.440 |
Why?
| | Coronavirus Infections | 3 | 2020 | 288 | 0.430 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 314 | 0.430 |
Why?
| | Blood Transfusion | 2 | 2022 | 162 | 0.420 |
Why?
| | Trachea | 1 | 2011 | 309 | 0.410 |
Why?
| | Glomerular Filtration Rate | 3 | 2022 | 390 | 0.410 |
Why?
| | Length of Stay | 8 | 2021 | 711 | 0.400 |
Why?
| | Prevalence | 10 | 2022 | 1284 | 0.400 |
Why?
| | Anti-Infective Agents | 2 | 2021 | 109 | 0.390 |
Why?
| | Drug Monitoring | 2 | 2021 | 121 | 0.390 |
Why?
| | Hypothermia, Induced | 2 | 2021 | 72 | 0.380 |
Why?
| | Out-of-Hospital Cardiac Arrest | 2 | 2021 | 48 | 0.380 |
Why?
| | Water-Electrolyte Imbalance | 2 | 2018 | 14 | 0.370 |
Why?
| | Immunotherapy, Adoptive | 2 | 2021 | 142 | 0.360 |
Why?
| | Resuscitation | 3 | 2017 | 95 | 0.360 |
Why?
| | HSP70 Heat-Shock Proteins | 4 | 2017 | 111 | 0.360 |
Why?
| | Emergency Service, Hospital | 3 | 2017 | 448 | 0.360 |
Why?
| | Chlorides | 2 | 2018 | 117 | 0.350 |
Why?
| | Algorithms | 5 | 2020 | 1856 | 0.350 |
Why?
| | Young Adult | 15 | 2022 | 6075 | 0.350 |
Why?
| | Neoplasms | 2 | 2021 | 2744 | 0.350 |
Why?
| | United States | 17 | 2022 | 6459 | 0.340 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 38 | 0.330 |
Why?
| | Respiratory Tract Infections | 2 | 2020 | 104 | 0.330 |
Why?
| | Databases, Factual | 7 | 2020 | 801 | 0.330 |
Why?
| | Cohort Studies | 9 | 2022 | 2742 | 0.330 |
Why?
| | Risk Assessment | 11 | 2020 | 2300 | 0.320 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2021 | 962 | 0.320 |
Why?
| | Pediatrics | 3 | 2016 | 349 | 0.310 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 16 | 0.310 |
Why?
| | Interleukin-8 | 4 | 2022 | 86 | 0.300 |
Why?
| | Logistic Models | 9 | 2021 | 1171 | 0.300 |
Why?
| | Age Factors | 6 | 2021 | 1928 | 0.300 |
Why?
| | Matrix Metalloproteinase 8 | 4 | 2017 | 4 | 0.290 |
Why?
| | Renal Replacement Therapy | 2 | 2022 | 25 | 0.280 |
Why?
| | Hypothermia | 2 | 2022 | 25 | 0.270 |
Why?
| | Complement Membrane Attack Complex | 2 | 2020 | 20 | 0.270 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2021 | 65 | 0.270 |
Why?
| | Creatinine | 3 | 2020 | 352 | 0.260 |
Why?
| | Antigens, CD19 | 2 | 2021 | 35 | 0.260 |
Why?
| | Pandemics | 4 | 2022 | 569 | 0.250 |
Why?
| | Europe | 3 | 2018 | 313 | 0.250 |
Why?
| | Combined Modality Therapy | 3 | 2021 | 1688 | 0.250 |
Why?
| | Granzymes | 3 | 2017 | 89 | 0.240 |
Why?
| | Disease Progression | 3 | 2018 | 1487 | 0.240 |
Why?
| | Immunologic Factors | 2 | 2021 | 165 | 0.240 |
Why?
| | Blood Banks | 1 | 2022 | 8 | 0.240 |
Why?
| | Osteonecrosis | 1 | 2022 | 23 | 0.240 |
Why?
| | Muscle Proteins | 2 | 2000 | 137 | 0.240 |
Why?
| | Child, Hospitalized | 1 | 2022 | 28 | 0.230 |
Why?
| | C-Reactive Protein | 2 | 2020 | 196 | 0.230 |
Why?
| | Time Factors | 6 | 2022 | 5526 | 0.230 |
Why?
| | Glucocorticoids | 2 | 2021 | 362 | 0.230 |
Why?
| | Blood Specimen Collection | 1 | 2021 | 35 | 0.220 |
Why?
| | Treatment Outcome | 10 | 2021 | 7997 | 0.220 |
Why?
| | Delirium | 1 | 2022 | 68 | 0.220 |
Why?
| | Erythrocytes | 1 | 2022 | 270 | 0.220 |
Why?
| | Thrombotic Microangiopathies | 1 | 2020 | 18 | 0.220 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 90 | 0.220 |
Why?
| | Vasoconstrictor Agents | 2 | 2020 | 53 | 0.210 |
Why?
| | France | 1 | 2020 | 51 | 0.210 |
Why?
| | Inflammation Mediators | 2 | 2020 | 161 | 0.210 |
Why?
| | Brain Diseases | 1 | 2021 | 189 | 0.210 |
Why?
| | Meningitis, Bacterial | 1 | 2020 | 13 | 0.210 |
Why?
| | Intubation | 1 | 2020 | 23 | 0.210 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2000 | 4 | 0.210 |
Why?
| | Chemokine CCL3 | 2 | 2017 | 11 | 0.210 |
Why?
| | Nervous System Diseases | 1 | 2021 | 150 | 0.200 |
Why?
| | Fingers | 1 | 2020 | 67 | 0.200 |
Why?
| | Hospitalization | 6 | 2022 | 785 | 0.200 |
Why?
| | Oximetry | 1 | 2020 | 89 | 0.200 |
Why?
| | Thiamine | 1 | 2019 | 8 | 0.200 |
Why?
| | Hemorrhage | 1 | 2021 | 251 | 0.200 |
Why?
| | Salvage Therapy | 1 | 2021 | 224 | 0.200 |
Why?
| | Nerve Tissue Proteins | 2 | 2000 | 531 | 0.190 |
Why?
| | Research Design | 2 | 2020 | 576 | 0.190 |
Why?
| | Anthracyclines | 1 | 2019 | 28 | 0.190 |
Why?
| | Emergency Medical Services | 1 | 2021 | 187 | 0.190 |
Why?
| | Clinical Coding | 1 | 2019 | 21 | 0.190 |
Why?
| | Staphylococcal Infections | 1 | 2022 | 290 | 0.190 |
Why?
| | Malnutrition | 1 | 2018 | 28 | 0.180 |
Why?
| | Afibrinogenemia | 1 | 2018 | 1 | 0.180 |
Why?
| | Homeodomain Proteins | 2 | 2000 | 551 | 0.180 |
Why?
| | Macrophage Activation Syndrome | 1 | 2018 | 2 | 0.180 |
Why?
| | Syndrome | 2 | 2017 | 436 | 0.180 |
Why?
| | Cell Adhesion Molecules | 1 | 2019 | 169 | 0.180 |
Why?
| | Ethical Review | 1 | 2018 | 8 | 0.180 |
Why?
| | Nutritional Status | 1 | 2018 | 82 | 0.180 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2013 | 345 | 0.180 |
Why?
| | Adrenal Cortex Hormones | 2 | 2018 | 266 | 0.180 |
Why?
| | Ethics Committees, Research | 1 | 2018 | 30 | 0.180 |
Why?
| | Chest Wall Oscillation | 1 | 2017 | 5 | 0.180 |
Why?
| | Acute Lung Injury | 1 | 2019 | 58 | 0.180 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2021 | 306 | 0.180 |
Why?
| | Brain Injuries | 1 | 2020 | 145 | 0.180 |
Why?
| | Lipids | 1 | 2020 | 388 | 0.180 |
Why?
| | Postoperative Complications | 2 | 2019 | 2296 | 0.170 |
Why?
| | Hemodynamics | 5 | 2021 | 719 | 0.170 |
Why?
| | Metabolic Diseases | 1 | 2018 | 54 | 0.170 |
Why?
| | Drug Prescriptions | 1 | 2019 | 134 | 0.170 |
Why?
| | Body Mass Index | 2 | 2018 | 790 | 0.170 |
Why?
| | Comorbidity | 2 | 2018 | 947 | 0.170 |
Why?
| | Clinical Alarms | 1 | 2017 | 15 | 0.170 |
Why?
| | User-Computer Interface | 1 | 2019 | 189 | 0.170 |
Why?
| | Health Resources | 1 | 2018 | 79 | 0.170 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2017 | 52 | 0.170 |
Why?
| | Isotonic Solutions | 1 | 2017 | 21 | 0.170 |
Why?
| | Textbooks as Topic | 1 | 2016 | 2 | 0.170 |
Why?
| | Interleukin-6 | 1 | 2018 | 239 | 0.160 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 580 | 0.160 |
Why?
| | Surgical Procedures, Operative | 1 | 2019 | 191 | 0.160 |
Why?
| | Ultrasonography | 2 | 2021 | 700 | 0.160 |
Why?
| | Skin | 1 | 2020 | 562 | 0.160 |
Why?
| | Tumor Lysis Syndrome | 1 | 2016 | 8 | 0.160 |
Why?
| | Electronic Health Records | 1 | 2020 | 287 | 0.160 |
Why?
| | Disabled Children | 1 | 2016 | 43 | 0.160 |
Why?
| | Heart | 1 | 2019 | 535 | 0.150 |
Why?
| | Steroids | 1 | 2016 | 176 | 0.150 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2016 | 80 | 0.150 |
Why?
| | Decision Support Techniques | 1 | 2017 | 163 | 0.150 |
Why?
| | Orthomyxoviridae | 1 | 2016 | 63 | 0.150 |
Why?
| | Virus Diseases | 1 | 2016 | 102 | 0.150 |
Why?
| | Practice Guidelines as Topic | 3 | 2019 | 1091 | 0.150 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2017 | 1213 | 0.150 |
Why?
| | Registries | 1 | 2019 | 686 | 0.140 |
Why?
| | Recombinant Fusion Proteins | 1 | 2017 | 570 | 0.140 |
Why?
| | Antibodies, Viral | 3 | 2022 | 347 | 0.140 |
Why?
| | ROC Curve | 4 | 2019 | 768 | 0.140 |
Why?
| | Models, Statistical | 2 | 2020 | 583 | 0.140 |
Why?
| | Survival Rate | 4 | 2021 | 1925 | 0.140 |
Why?
| | Odds Ratio | 3 | 2022 | 686 | 0.130 |
Why?
| | Models, Biological | 2 | 2019 | 1796 | 0.130 |
Why?
| | Pulmonary Gas Exchange | 1 | 2013 | 35 | 0.130 |
Why?
| | Phenotype | 5 | 2022 | 2324 | 0.130 |
Why?
| | Point-of-Care Systems | 1 | 2015 | 134 | 0.130 |
Why?
| | Proteolysis | 1 | 2014 | 100 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 344 | 0.130 |
Why?
| | Cross Infection | 1 | 2015 | 193 | 0.130 |
Why?
| | Recurrence | 1 | 2017 | 1202 | 0.130 |
Why?
| | Kidney | 1 | 2020 | 1245 | 0.130 |
Why?
| | Macrophage Activation | 1 | 2013 | 45 | 0.130 |
Why?
| | Case-Control Studies | 4 | 2020 | 1836 | 0.130 |
Why?
| | Antibodies, Bispecific | 1 | 2013 | 18 | 0.130 |
Why?
| | Program Evaluation | 1 | 2015 | 303 | 0.130 |
Why?
| | Immune System Diseases | 1 | 2013 | 25 | 0.130 |
Why?
| | Survival Analysis | 4 | 2019 | 1597 | 0.120 |
Why?
| | Rats, Sprague-Dawley | 3 | 2022 | 1367 | 0.120 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2014 | 172 | 0.120 |
Why?
| | Protein Kinases | 1 | 2014 | 226 | 0.120 |
Why?
| | Gagging | 1 | 2011 | 2 | 0.120 |
Why?
| | Metapneumovirus | 1 | 2011 | 4 | 0.120 |
Why?
| | Subcutaneous Emphysema | 1 | 2011 | 6 | 0.120 |
Why?
| | Paramyxoviridae Infections | 1 | 2011 | 6 | 0.120 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 5 | 0.120 |
Why?
| | Mediastinal Emphysema | 1 | 2011 | 7 | 0.120 |
Why?
| | RNA, Messenger | 2 | 2017 | 2015 | 0.120 |
Why?
| | Influenza, Human | 1 | 2016 | 387 | 0.120 |
Why?
| | Sensitivity and Specificity | 4 | 2020 | 2092 | 0.120 |
Why?
| | Clinical Protocols | 3 | 2017 | 158 | 0.120 |
Why?
| | Stress, Physiological | 1 | 2014 | 247 | 0.110 |
Why?
| | Positive-Pressure Respiration | 1 | 2011 | 49 | 0.110 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 167 | 0.110 |
Why?
| | Autistic Disorder | 1 | 2011 | 142 | 0.110 |
Why?
| | Immunomodulation | 2 | 2021 | 58 | 0.110 |
Why?
| | Animals | 11 | 2022 | 27277 | 0.110 |
Why?
| | Equipment Design | 1 | 2011 | 425 | 0.100 |
Why?
| | Incidence | 3 | 2021 | 1659 | 0.100 |
Why?
| | Chromatography, Liquid | 2 | 2021 | 104 | 0.100 |
Why?
| | Bronchoscopy | 1 | 2011 | 151 | 0.100 |
Why?
| | Mitochondria | 1 | 2014 | 537 | 0.100 |
Why?
| | Vomiting | 1 | 2011 | 186 | 0.100 |
Why?
| | Patient Discharge | 2 | 2022 | 231 | 0.100 |
Why?
| | Acute Disease | 3 | 2018 | 878 | 0.100 |
Why?
| | Radiography | 1 | 2011 | 877 | 0.100 |
Why?
| | Seizures | 1 | 2011 | 279 | 0.100 |
Why?
| | Rats | 3 | 2022 | 4360 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 3309 | 0.090 |
Why?
| | Neurons | 1 | 2018 | 1618 | 0.090 |
Why?
| | Morbidity | 2 | 2020 | 148 | 0.090 |
Why?
| | Adult | 7 | 2022 | 26295 | 0.090 |
Why?
| | Oxygen | 1 | 2013 | 735 | 0.090 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2014 | 676 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 926 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 994 | 0.090 |
Why?
| | Decision Trees | 2 | 2019 | 68 | 0.090 |
Why?
| | Mice | 7 | 2020 | 11276 | 0.080 |
Why?
| | Fluid Therapy | 2 | 2017 | 49 | 0.080 |
Why?
| | Philadelphia | 2 | 2017 | 11 | 0.080 |
Why?
| | Factor IX | 1 | 2006 | 6 | 0.080 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 2438 | 0.080 |
Why?
| | Diagnosis, Differential | 2 | 2021 | 1612 | 0.080 |
Why?
| | Hepatocytes | 1 | 2006 | 125 | 0.070 |
Why?
| | Mice, Inbred BALB C | 2 | 2018 | 1080 | 0.070 |
Why?
| | Cause of Death | 2 | 2017 | 282 | 0.070 |
Why?
| | Adenovirus E1 Proteins | 1 | 2003 | 1 | 0.070 |
Why?
| | HIV Antigens | 1 | 2003 | 4 | 0.070 |
Why?
| | Gene Products, gag | 1 | 2003 | 14 | 0.070 |
Why?
| | AIDS Vaccines | 1 | 2003 | 9 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2018 | 2825 | 0.070 |
Why?
| | Adenoviruses, Human | 1 | 2003 | 41 | 0.070 |
Why?
| | Immunization, Secondary | 1 | 2003 | 27 | 0.070 |
Why?
| | PAX7 Transcription Factor | 2 | 2000 | 4 | 0.060 |
Why?
| | DNA-Binding Proteins | 2 | 2000 | 1215 | 0.060 |
Why?
| | Academic Medical Centers | 2 | 2017 | 396 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2021 | 1778 | 0.060 |
Why?
| | Thrombomodulin | 1 | 2022 | 8 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2020 | 3239 | 0.060 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2022 | 75 | 0.060 |
Why?
| | Neutralization Tests | 1 | 2022 | 86 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1016 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2020 | 2709 | 0.060 |
Why?
| | Blood Component Transfusion | 1 | 2021 | 12 | 0.060 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2022 | 54 | 0.060 |
Why?
| | Aftercare | 1 | 2022 | 52 | 0.060 |
Why?
| | Viral Envelope Proteins | 1 | 2022 | 102 | 0.060 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2022 | 61 | 0.060 |
Why?
| | Antifibrinolytic Agents | 1 | 2021 | 25 | 0.060 |
Why?
| | Italy | 1 | 2021 | 106 | 0.060 |
Why?
| | Transcription Factors | 2 | 2000 | 1530 | 0.060 |
Why?
| | Models, Theoretical | 2 | 2015 | 488 | 0.060 |
Why?
| | Canada | 1 | 2021 | 211 | 0.050 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 99 | 0.050 |
Why?
| | Propensity Score | 1 | 2021 | 135 | 0.050 |
Why?
| | Neuroimaging | 1 | 2021 | 100 | 0.050 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2022 | 130 | 0.050 |
Why?
| | Age Distribution | 1 | 2021 | 216 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2020 | 80 | 0.050 |
Why?
| | Piperacillin | 1 | 2020 | 10 | 0.050 |
Why?
| | Penicillanic Acid | 1 | 2020 | 14 | 0.050 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 26 | 0.050 |
Why?
| | Erythrocyte Count | 1 | 2020 | 23 | 0.050 |
Why?
| | Temperature | 1 | 2022 | 420 | 0.050 |
Why?
| | APACHE | 1 | 2020 | 21 | 0.050 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2020 | 41 | 0.050 |
Why?
| | Streptococcus agalactiae | 1 | 2020 | 16 | 0.050 |
Why?
| | Lymphocyte Activation | 1 | 2003 | 823 | 0.050 |
Why?
| | Cerebrospinal Fluid | 1 | 2020 | 39 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2020 | 173 | 0.050 |
Why?
| | Age of Onset | 1 | 2021 | 320 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2003 | 519 | 0.050 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2000 | 54 | 0.050 |
Why?
| | Punctures | 1 | 2019 | 30 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 2020 | 98 | 0.050 |
Why?
| | Ligation | 1 | 2019 | 59 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2020 | 225 | 0.050 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2000 | 102 | 0.050 |
Why?
| | False Positive Reactions | 1 | 2020 | 227 | 0.050 |
Why?
| | Rhabdomyosarcoma | 1 | 1999 | 43 | 0.050 |
Why?
| | Streptococcal Infections | 1 | 2020 | 65 | 0.050 |
Why?
| | Sarcoma, Ewing | 1 | 1999 | 42 | 0.050 |
Why?
| | Cecum | 1 | 2019 | 74 | 0.050 |
Why?
| | Nephritis, Interstitial | 1 | 2020 | 50 | 0.050 |
Why?
| | Fungi | 1 | 2020 | 72 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2022 | 437 | 0.050 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 133 | 0.050 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2020 | 64 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2020 | 374 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2021 | 3889 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2020 | 171 | 0.050 |
Why?
| | Cystatin C | 1 | 2019 | 31 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 413 | 0.050 |
Why?
| | Osteopontin | 1 | 2019 | 53 | 0.050 |
Why?
| | Regression Analysis | 1 | 2021 | 631 | 0.050 |
Why?
| | Viruses | 1 | 2020 | 85 | 0.050 |
Why?
| | RNA, Viral | 1 | 2020 | 345 | 0.050 |
Why?
| | South America | 1 | 2018 | 31 | 0.050 |
Why?
| | Lactic Acid | 1 | 2019 | 119 | 0.050 |
Why?
| | Forkhead Transcription Factors | 1 | 2000 | 162 | 0.050 |
Why?
| | Translocation, Genetic | 1 | 2000 | 263 | 0.050 |
Why?
| | Area Under Curve | 1 | 2019 | 346 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2022 | 456 | 0.050 |
Why?
| | Neurosurgery | 1 | 2020 | 78 | 0.050 |
Why?
| | Asia | 1 | 2018 | 96 | 0.050 |
Why?
| | Linear Models | 1 | 2020 | 435 | 0.050 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 115 | 0.050 |
Why?
| | Ghrelin | 1 | 2018 | 22 | 0.050 |
Why?
| | Recovery of Function | 1 | 2020 | 265 | 0.050 |
Why?
| | Coma | 1 | 2018 | 40 | 0.050 |
Why?
| | Hyperphagia | 1 | 2018 | 35 | 0.050 |
Why?
| | Hospital Costs | 1 | 2019 | 103 | 0.040 |
Why?
| | North America | 1 | 2018 | 180 | 0.040 |
Why?
| | Stroke Volume | 1 | 2021 | 448 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2020 | 485 | 0.040 |
Why?
| | Pilot Projects | 1 | 2021 | 840 | 0.040 |
Why?
| | Neutrophils | 1 | 2019 | 296 | 0.040 |
Why?
| | Ohio | 1 | 2017 | 39 | 0.040 |
Why?
| | Infant, Premature | 1 | 2020 | 289 | 0.040 |
Why?
| | Leptin | 1 | 2018 | 114 | 0.040 |
Why?
| | Calcitonin | 1 | 2017 | 44 | 0.040 |
Why?
| | Serum Amyloid A Protein | 1 | 2017 | 25 | 0.040 |
Why?
| | International Cooperation | 1 | 2017 | 135 | 0.040 |
Why?
| | Acidosis | 1 | 2017 | 63 | 0.040 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2018 | 126 | 0.040 |
Why?
| | Vital Signs | 1 | 2017 | 40 | 0.040 |
Why?
| | Cardiovascular Agents | 1 | 2017 | 57 | 0.040 |
Why?
| | Sodium Chloride | 1 | 2017 | 93 | 0.040 |
Why?
| | Chemokines, CC | 1 | 2016 | 32 | 0.040 |
Why?
| | Kinetics | 1 | 2019 | 1628 | 0.040 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2016 | 36 | 0.040 |
Why?
| | Nasopharynx | 1 | 2016 | 44 | 0.040 |
Why?
| | Bacteria | 1 | 2020 | 466 | 0.040 |
Why?
| | Spleen | 1 | 2017 | 513 | 0.040 |
Why?
| | Neuroblastoma | 1 | 1999 | 369 | 0.040 |
Why?
| | Myeloblastin | 1 | 2015 | 5 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 286 | 0.040 |
Why?
| | Specimen Handling | 1 | 2016 | 112 | 0.040 |
Why?
| | Anesthesia | 1 | 2017 | 174 | 0.040 |
Why?
| | Pleural Effusion | 1 | 2015 | 48 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2015 | 133 | 0.040 |
Why?
| | Obesity | 1 | 2022 | 978 | 0.040 |
Why?
| | Glucose | 1 | 2018 | 630 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 288 | 0.040 |
Why?
| | Pneumothorax | 1 | 2015 | 51 | 0.040 |
Why?
| | Fever | 1 | 2015 | 126 | 0.040 |
Why?
| | Pregnancy | 1 | 2022 | 2845 | 0.030 |
Why?
| | Chaperonin 60 | 1 | 2014 | 8 | 0.030 |
Why?
| | Motor Activity | 1 | 2017 | 337 | 0.030 |
Why?
| | Inflammation | 1 | 2020 | 859 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2022 | 2342 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2017 | 1026 | 0.030 |
Why?
| | Serine Endopeptidases | 1 | 2015 | 175 | 0.030 |
Why?
| | Melanoma | 1 | 1999 | 519 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2021 | 1197 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2017 | 381 | 0.030 |
Why?
| | Respiratory Rate | 1 | 2013 | 18 | 0.030 |
Why?
| | Consensus | 1 | 2015 | 304 | 0.030 |
Why?
| | Cardiomyopathies | 1 | 2017 | 265 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2016 | 162 | 0.030 |
Why?
| | Caspase 3 | 1 | 2014 | 176 | 0.030 |
Why?
| | Heat-Shock Response | 1 | 2014 | 44 | 0.030 |
Why?
| | Sleep | 1 | 2018 | 438 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2014 | 448 | 0.030 |
Why?
| | Receptors, Interleukin-6 | 1 | 2013 | 17 | 0.030 |
Why?
| | Observer Variation | 1 | 2015 | 622 | 0.030 |
Why?
| | Transcriptome | 1 | 2018 | 534 | 0.030 |
Why?
| | Quality Improvement | 1 | 2017 | 374 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2014 | 244 | 0.030 |
Why?
| | Down Syndrome | 1 | 2013 | 56 | 0.030 |
Why?
| | Genetic Vectors | 2 | 2006 | 447 | 0.030 |
Why?
| | Sex Factors | 1 | 2017 | 1097 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2013 | 250 | 0.030 |
Why?
| | Mortality | 1 | 2014 | 150 | 0.030 |
Why?
| | Sirolimus | 1 | 2014 | 173 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 973 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2014 | 739 | 0.030 |
Why?
| | Burns | 1 | 2013 | 107 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 902 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2014 | 648 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2016 | 345 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2347 | 0.030 |
Why?
| | Cell Survival | 1 | 2014 | 1017 | 0.030 |
Why?
| | Biomedical Research | 1 | 2015 | 359 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2015 | 345 | 0.030 |
Why?
| | Apoptosis | 1 | 2014 | 1782 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2006 | 332 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2006 | 171 | 0.020 |
Why?
| | Gene Transfer Techniques | 1 | 2006 | 161 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2006 | 272 | 0.020 |
Why?
| | Adenoviridae | 1 | 2006 | 348 | 0.020 |
Why?
| | Immunization Schedule | 1 | 2003 | 22 | 0.020 |
Why?
| | Vaccinia virus | 1 | 2003 | 17 | 0.020 |
Why?
| | Vaccines, DNA | 1 | 2003 | 15 | 0.020 |
Why?
| | Injections, Intramuscular | 1 | 2003 | 66 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2006 | 283 | 0.020 |
Why?
| | Immune Tolerance | 1 | 2006 | 349 | 0.020 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2003 | 89 | 0.020 |
Why?
| | HeLa Cells | 1 | 2003 | 512 | 0.010 |
Why?
| | Pan troglodytes | 1 | 2003 | 194 | 0.010 |
Why?
| | Paired Box Transcription Factors | 1 | 1999 | 53 | 0.010 |
Why?
| | Plasmids | 1 | 1999 | 292 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1999 | 432 | 0.010 |
Why?
| | Cell Line | 1 | 2003 | 2625 | 0.010 |
Why?
| | Alternative Splicing | 1 | 1999 | 193 | 0.010 |
Why?
| | Aged | 1 | 2016 | 18700 | 0.010 |
Why?
| | Exons | 1 | 1999 | 464 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1999 | 1089 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 25832 | 0.010 |
Why?
| | Base Sequence | 1 | 1999 | 2421 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1999 | 2164 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1999 | 1169 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1999 | 3187 | 0.010 |
Why?
| | Models, Genetic | 1 | 1999 | 927 | 0.010 |
Why?
|
|
Fitzgerald's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|